Dendritic cell dysfunction restrains cytotoxic T cell responses against cancer
Although immune checkpoint blockade (ICB) therapy can induce durable survival benefits in patients with advanced cancer, most patients do not respond. ICB acts by reinvigorating pre-existing anti-tumor immune responses, and responders are often characterized by the presence of a T cell infiltrate in...
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Thesis |
| Published: |
Massachusetts Institute of Technology
2023
|
| Online Access: | https://hdl.handle.net/1721.1/150065 |